The first therapeutic device has been approved for use in non-small cell lung cancer (NSCLC). Novocure's therapeutic device, in combination with an NSCLC medication, demonstrated to improve patients' overall survival and won the approval of the U.S. regulatory authority. In South Korea, Nu Eyne is researching the potential of oncology therapeutic devices through clinical studies.

According to industry sources on October 19th, the U.S. Food and Drug Administration (FDA) granted approval for Novocure's Optune Lua for the treatment of metastatic non-small cell lung cancer (NSCLC). Optune Lua is approved for use in combination with PD-1/PD-L1 immunotherapy for cancer or docetaxel.

Optune Lu